Advances in cell-based screening in drug discovery 2024

Revolution in resolution: Single cell technologies in drug discovery
Wednesday, July 3, at 15:00 BST / 16:00 CEST / 10:00 EDT / 07:00 PDT

Core facilities harnessing data "perennity" in life sciences
Wednesday, July 3, at 16:00 BST / 17:00 CEST / 11:00 EDT / 08:00 PDT

High throughput target confirmation by arrayed single cell transcriptomics to verify Treg differentiation
Wednesday, July 3, at 17:00 BST / 18:00 CEST / 12:00 EDT / 09:00 PDT

Cell high throughput screening: Workflows, challenges, and future direction
Wednesday, July 3, at 18:00 BST / 19:00 CEST / 13:00 EDT / 10:00 PDT

Your exclusive access to SelectScience's collaboration with ELRIG, providing high-quality presentations from the ELRIG 'Advances in cell-based assays' event from AstraZeneca, Gothenburg. Join this one-day event and register for specific presentations for new insights, new methods, technologies, and the latest advancements in cell assay screening and applications.

Revolution in resolution: Single cell technologies in drug discovery

Gitte Neubauer
Vice President of Omics Technology
& Head of Cellzome
Cellzome, a GSK company
(talk presented by Christine Rummel, Cellzome)

The field of single cell technologies has seen a revolution over the past decade. In particular commercially available instrumentation and kits allowed the broad applicability of omics analyses in drug discovery and development, enabling forward and reverse translation and a deep understanding of biological processes underlying disease progression and target function. The rapid development in spatial omics technologies is now undergoing a similar revolution and will provide single cell resolution in spatial tissue context. This presentation will give an overview over current technologies and provide vignettes of applications from our team at GSK.

Core facilities harnessing data "perennity" in life sciences

Pr. Spencer Shorte
Director to the Center for
Technology Research & Resources
Institut Pasteur (Paris)

During the last five decades there has been a paradigm shift in life sciences research toward automation, driven mainly by the need for high-throughput screening in therapeutics discovery, and omics. This trend has resonated for basic research, with the profound impact of machine- and deep-learning (ML/DL) based analyses. While ML/DL provides an unprecedented opportunity for modern life science it also risks confounding biases, amplifying artefacts. To minimize such risks demands assuring the highest possible quality of data production, methodological rigor, and reproducibility. One important way this can be systematically achieved is by structuring technology research infrastructure and operations. Based on twenty-five years’ experience, we present our vision and perspective on this problem, pointing out how core facilities are redefining the way research organizations operate. Inside core facilities data quality-management guarantees empirical data satisfy not only a means to an experimental endpoint, but also the data’s "perennity" to the future benefit of the global life sciences community.

High throughput target confirmation by arrayed single cell transcriptomics to verify Treg differentiation

Christine Rummel
Scientific Investigator
Cellzome, a GSK company

Regulatory CD4 positive T-lymphocytes (Tregs) control the immune response to self and foreign antigens. By suppressing other immune cells, Tregs help to sustain immunological self-tolerance and homeostasis to prevent autoimmunity, and responses to harmless antigens. This project aims to use targeted gene knockouts (KOs) in combination with skewing stimulation, to increase the Treg (CD127low/FOXP3positive) population in CD4 positive T-Cells.

In this work, we describe the detailed analysis of over 60 target genes using 2 different single-cell platforms: 1) CITE-seq (RNA and surface protein based on 10X Genomics) and 2) combinatorial indexing (SplitSeq, commercialized by Parse Biosciences) which drastically improves the throughput of single-cell transcriptomics sample preparation. Both methods resulted in high quality datasets consisting of more than 1.7 million cells, thus enabling cost effective target selection from high throughput screens.

Cell high throughput screening: Workflows, challenges, and future direction

Mercedes Vazquez-chantada
Cellular Biologist
AstraZeneca

There is a constant need to develop drugs faster for treating human diseases and thus technology developers have for years invested in developing “the next big thing” that can support the need for efficiency in drug discovery. Automation in drug discovery, not only allows faster data generation, but contributes to better decision making based on consistent data and reducing the resources needed. Artificial Intelligence, machine learning, automation and robotics are only a few examples of technologies that can accelerate and transform drug discovery processes. This insightful webinar will discuss high throughput screening in small molecules. As we explore new modalities, this session will delve into innovative workflows, address current challenges, and discuss future directions in the field.